{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:46:43Z","timestamp":1791946003207,"version":"4.3.4"},"reference-count":145,"publisher":"Informa UK Limited","issue":"17","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2019,11,22]]},"DOI":"10.1080\/14656566.2019.1660772","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T23:35:35Z","timestamp":1568072135000},"page":"2169-2184","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":156,"title":["The latest advances in \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections"],"prefix":"10.1080","volume":"20","author":[{"given":"Krisztina M.","family":"Papp-Wallace","sequence":"first","affiliation":[{"name":"Louis Stokes Cleveland Department of Veterans Affairs, Research Service, Cleveland, OH, USA"},{"name":"Department of Medicine, Case Western Reserve University, Cleveland, OH, USA"},{"name":"Department of Biochemistry, Case Western Reserve University, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,9,9]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.1980.0049"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2019.04.002"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0159-8"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix893"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00622"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00037-09"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2019.05.006"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2019.1647781"},{"key":"CIT0009","volume-title":"ZERBAXA\u00ae (ceftolozane and tazobactam) for injection, for intravenous use","author":"Merck & Co., Inc","year":"2014"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1447381"},{"key":"CIT0011","volume-title":"Ceftolozane and tazobactam for the treatment of bacterial infections: a review of clinical effectiveness, cost-effectiveness, and guidelines","year":"2016"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.05.019"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00743-09"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00693-09"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2019.04.003:S1684-182(18)30315-3"},{"key":"CIT0016","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13756-017-0264-2","volume":"6","author":"Prabhu VS","year":"2017","journal-title":"Antimicrob Resist Infect Control"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz147"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.01.015"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.11.021"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02431-18"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S175679"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku184"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.01.032"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01802-13"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01404-13"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx468"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.04.004"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw374"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1556\/1886.2019.00001"},{"key":"CIT0030","doi-asserted-by":"crossref","first-page":"e02125","DOI":"10.1128\/AAC.00313-18","volume":"62","author":"Castanheira M","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00533-18"},{"key":"CIT0032","first-page":"9095203","volume":"2018","author":"Skoglund E","year":"2018","journal-title":"Case Rep Infect Dis"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx424"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02085-18"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01183-17"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01117-17"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00825-15"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02462-13"},{"key":"CIT0039","volume-title":"AVYCAZ (ceftazidime and avibactam) for injection, for intravenous use","author":"Allergan USA, Inc","year":"2019"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0902-x"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-017-1096-y"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00641-09"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00756-10"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00592-18"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01045-17"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp197"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.485979"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00528-17"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01165-15"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00678-15"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02097-16"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv094"},{"key":"CIT0054","volume-title":"VABOMERE\u00ae (meropenem and vaborbactam) for injection, for intravenous use","author":"Melinta Therapeutics, Inc","year":"2019"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0214-1"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2092"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1512586"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1542300"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018763288"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.05.031"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00711-16"},{"key":"CIT0062","first-page":"e01904","volume":"62","author":"Hackel MA","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00567-17"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy576"},{"key":"CIT0065","doi-asserted-by":"crossref","first-page":"e01665","DOI":"10.1128\/AAC.01665-18","volume":"63","author":"Sabet M","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-17"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01694-17"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02048-18"},{"key":"CIT0069","volume-title":"RECARBRIO\u2122 (imipenem, cilastatin, and relebactam) for injection, for intravenous use","author":"Merck & Co., Inc","year":"2019"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00169-18"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.02.018"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02209-16"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00174-18"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02406-17"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02577-17"},{"key":"CIT0076","volume-title":"O0284: Imipenem-relebactam efficiently inhibits D179 variants of the KPC-2 \u03b2-lactamase European Congress of clinical microbiology and infectious diseases","author":"Barnes MD","year":"2019"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00642-17"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2018.0065"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00573-18"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00830-15"},{"key":"CIT0081","first-page":"2286","volume":"68","author":"Livermore DM","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"CIT0082","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.2046"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv166"},{"key":"CIT0084","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02529-16"},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.104"},{"key":"CIT0086","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0b013e31824237ce"},{"key":"CIT0087","doi-asserted-by":"publisher","DOI":"10.1177\/106002809502900601"},{"key":"CIT0088","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.6226"},{"key":"CIT0089","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.04.014"},{"key":"CIT0090","first-page":"318","volume":"68","author":"Beique L","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"CIT0091","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-3-717"},{"key":"CIT0092","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24076"},{"key":"CIT0093","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp131"},{"key":"CIT0094","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2006.11.011"},{"key":"CIT0095","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02123-13"},{"key":"CIT0096","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00206-15"},{"key":"CIT0097","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02379-15"},{"key":"CIT0098","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01989-12"},{"key":"CIT0099","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku568"},{"key":"CIT0100","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens4030620"},{"key":"CIT0101","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00514-19"},{"key":"CIT0102","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00105-19"},{"key":"CIT0103","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00033-15"},{"key":"CIT0104","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00159-19"},{"key":"CIT0105","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix182"},{"key":"CIT0106","doi-asserted-by":"crossref","first-page":"e01576","DOI":"10.1128\/AAC.01576-17","volume":"62","author":"McLeod SM","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0107","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02409-16"},{"key":"CIT0108","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.08.011"},{"key":"CIT0109","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx360"},{"key":"CIT0114","volume-title":"1370: Cefepime\/VNRX-5133 broad-spectrum activity is maintained against emerging KPC- and PDC-variants in multidrug resistant K. pneumoniae and P. aeruginosa. ID Week","author":"Daigle D","year":"2018"},{"key":"CIT0119","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00072-17"},{"key":"CIT0120","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw593"},{"key":"CIT0121","volume":"8","author":"Thomson KS","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"CIT0122","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx050"},{"key":"CIT0123","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00091"},{"key":"CIT0124","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01238-17"},{"key":"CIT0125","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00128-19"},{"key":"CIT0126","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00948-18"},{"key":"CIT0127","doi-asserted-by":"crossref","first-page":"e01931","DOI":"10.1128\/AAC.01931-18","volume":"63","author":"Almarzoky Abuhussain SS","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0128","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02146-18"},{"key":"CIT0129","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00233-19"},{"key":"CIT0134","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00432-19"},{"key":"CIT0135","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky522"},{"key":"CIT0137","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02382-18"},{"key":"CIT0138","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02596-17"},{"key":"CIT0139","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw230"},{"key":"CIT0140","volume-title":"SUNDAY-AAR-714: The novel \u03b2-lactamase inhibitor ETX1317 restores the activity of cefpodoxime against drug-resistant Enterobacteriaceae ASM Microbe","author":"McLeod S","year":"2019"},{"key":"CIT0143","volume-title":"SUNDAY-AAR-715: Cefpodoxime-ETX1317 susceptibility is unaffected by ceftazidime-avibactam resistance mutations V240G, D179Y and D179Y\/T243M in KPC-3 \u03b2-lactamase ASM Microbe","author":"Shapiro A","year":"2019"},{"key":"CIT0145","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx035"},{"key":"CIT0146","volume-title":"SUNDAY-AAR-718 - Antimicrobial activity of ceftibuten-clavulanate when tested against clinical Enterobacteriaceae isolates collected worldwide in 2017 ASM Microbe","author":"Sader HS","year":"2019"},{"key":"CIT0147","volume-title":"SATURDAY-AAR-780: Ceftibuten-clavulanate activity against extended-spectrum-\u03b2-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae ASM Microbe","author":"Sader HS","year":"2019"},{"key":"CIT0148","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00144-19"},{"key":"CIT0149","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00145-19"},{"key":"CIT0150","volume-title":"MEDI 259: Discovery of VNRX-7145: A broad-spectrum orally bioavailable \u03b2-lactamase inhibitor (BLI) for highly resistant bacterial infections (\u201csuperbugs\u201d)","author":"Burns CJ","year":"2019"},{"key":"CIT0151","volume-title":"SUNDAY-AAR-720: The orally bioavailable \u03b2-lactamase inhibitor VNRX-7145 restores bactericidal activity of ceftibuten against Enterobacteriaceae expressing Ambler class A, C, and\/or D enzymes ASM Microbe","author":"Hamrick JC","year":"2019"},{"key":"CIT0152","volume-title":"SUNDAY-AAR-719: Rescue of ceftibuten activity by the oral \u03b2-lactamase inhibitor VNRX-7145 against Enterobacteriaceae expressing class A, C and\/or D \u03b2-lactamases ASM Microbe","author":"John KJ","year":"2019"},{"key":"CIT0153","volume-title":"SUNDAY-AAR-721: In vitro activity of ceftibuten in combination with VNRX-7145 and comparators against 1,066 UTI isolates non-susceptible to amoxicillin-clavulanate and levofloxacin ASM Microbe","author":"Hackel M","year":"2019"},{"key":"CIT0156","volume-title":"SUNDAY-AAR-726: Efficacy of ceftibuten + VNRX-7145 a novel \u03b2-lactamase inhibitor against ESBL E. coli strains in a murine UTI model ASM Microbe","author":"Pulse ME","year":"2019"},{"key":"CIT0157","volume-title":"SUNDAY-AAR-727:Assessmentof the in vivo pharmacodynamic profile of ceftibuten (CTB)\/VNRX-7145 combination against serine \u03b2-lactamase-producing Enterobacteriaceae (SBL-EB) in the neutropenic murine thigh infection model ASM Microbe","author":"Avery LM","year":"2019"},{"key":"CIT0162","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00630-17"},{"key":"CIT0163","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02943-15"},{"key":"CIT0164","volume-title":"US 10,206,937 B2: Boronic acid derivatives and therapeutic uses thereof","author":"Reddy RK","year":"2019"},{"key":"CIT0166","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01389"},{"key":"CIT0171","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.9b00031"},{"key":"CIT0172","volume-title":"The innovator\u2019s prescriptions: a disruptive solution for healthcare","author":"Christensen C","year":"2009"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2019.1660772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T20:17:57Z","timestamp":1664309877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2019.1660772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,9]]},"references-count":145,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2019,11,22]]}},"alternative-id":["10.1080\/14656566.2019.1660772"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2019.1660772","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}